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Objectives
Riociguat, an oral soluble guanylate cyclase (sGC) stimu-
lator, is a new candidate for treatment of pulmonary
hypertension (PH). Riociguat increases cGMP produc-
tion through a novel dual mode of action: direct NO-
independent stimulation of sGC and increasing sensitiv-
ity of sGC to low levels of NO. Another sGC stimulator,
BAY 41-2272, has shown anti-platelet activity in animal
models, as have BAY 41-2272 and riociguat in washed
human platelets, although bleeding has not been noted
as an adverse event (AE) in riociguat clinical studies
[1,2]. As riociguat and aspirin are likely to be used
together in PH, it was of interest to investigate potential
PD and PK interactions.
Methods
In this randomized, open-label, crossover study, partici-
pants took 2.5 mg/day riociguat, two morning doses of
500 mg aspirin, or both drugs concomitantly.
Results
Eighteen healthy men were enrolled. Six of 17 partici-
pants in the safety evaluation reported ≥1 treatment-
emergent AE. All AEs were mild except 1 case of mod-
erate headache following riociguat administration. Fif-
teen participants were valid for PD/PK analysis.
Riociguat PK values were independent of aspirin coad-
ministration. One hour after coadministration of rioci-
guat and aspirin, the mean increase in fraction unbound
was 19% for riociguat and 24% for its metabolite M-1
(BAY 60-4552) indicating mild displacement by salicylic
acid, the main aspirin metabolite. Effects of aspirin on
bleeding time, platelet aggregation and plasma throm-
boxane B2 were not affected by concomitant riociguat.
Riociguat alone had no effect on PD variables.
Conclusion
Riociguat demonstrated no clinically relevant PD or PK
interaction with aspirin. Coadministration of riociguat
and aspirin does not require dose adjustment. Phase 3
randomized controlled trials are investigating riociguat
in chronic thromboembolic pulmonary hypertension or
pulmonary arterial hypertension.
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